Grace Dy, MD
Grace Dy, MD
Associate Professor of Oncology, Department of Medicine
Roswell Park Cancer Institute
Clinical Assistant Professor
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Areas of Expertise:
Lung cancer
Mesothelioma
Thymic malignancies
Special Interests:
Phase I clinical trials
Novel targets for lung cancer therapy
Background
Education and Training:
MD - University of Santo Tomas, Manila, Philippines
Residency:
Mayo Clinic College of Medicine, Rochester, MN
Fellowship:
Mayo Clinic College of Medicine, Rochester, MN
Board Certification:
Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
- Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.Journal of thoracic oncology 2012; 72:419-426
- Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Journal of thoracic oncology 2012; 75:919-922
- Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Journal of hepatology 2012; 561:176-183
- Dy GK. EGFR tyrosine kinase inhibitors in lung cancer: Clinical implications of mutations and treatment resistance. International journal of targeted therapies in cancer 2012; September:50-54
- Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical cancer research 2012; 187:2048-2055
- Shao H, Tang H, Salavaggione OE, Yu C, Hylander B, Tan W, Repasky E, Adjei AA, Dy GK. Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer. Journal of thoracic oncology 2011; 66:998-1005
- Lorusso PM, Jin JY, Cheeti S, Chang I, Colburn D, Low JA, Leichman L, Berlin J, Adjei A, Dy G, Jimeno A, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clinical cancer research 2011;1717:5774-5782
- Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Phase II Trial of Sunitinib Maintenance Therapy After Platinum-Based Chemotherapy in Patients with Extensive-Stage Small Cell Lung Cancer. Journal of thoracic oncology 2011; 66:1117-1120
- Dy GK , Schild SE , Mandrekar S , Nair S , Wender DB , Steen PD , Molina JR , Rowland Jr KM , Hillman SL , Adjei AA. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: north Central Cancer Treatment Group Study N0326. Cancer 2010;11624:5686-5693
- Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KLA, Endo C, Molina JR, Schild SE, Adjei AA.Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Journal of thoracic oncology 2010; 59:1346-1353
- Dy GK. Dalotuzumab. Humanized anti-CD221 monoclonal antibody oncolytic. Drugs of the future 2010;358:609-612
- Dy G. MEK/MAPK inhibitors. Journal of thoracic oncology 2010; 512 Suppl. 6:S474-S475
- Dy G. Novel taxanes/epothilones. Journal of thoracic oncology 2010; 512 Suppl. 6:S490-S491
- Adjei AA, Schild SE, Rowland Jr KM, Stella PJ, Ziegler KLA, Gandara DR, Adjei AA, Molina JR, Dy GK, Mandrekar SJ, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of clinical oncology 2010; 284:614-619
- Dy G. SRC inhibitors. Journal of thoracic oncology 2010; 512 Suppl. 6:S466-S467
- Dy GK, Adjei AA. Emerging therapeutic targets in non-small cell lung cancer. Proceedings of the American Thoracic Society 2009; 62:218-223
- Dy GK, Hobday TJ, Nelson G, Windschitl HE, O'Connell MJ, Alberts SR, Goldberg RM, Nikcevich DA, Sargent DJ. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clinical colorectal cancer 2009; 82:88-93
- Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N, Adjei AA.Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results). Annals of thoracic surgery 2009; 882:385-390; discussion 390-391
- Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer research 2008; 6815:6145-6153
- Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic proceedings 2008; 833:355-367
- Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008; 1137 Suppl.:1857-1887
- Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames MM, Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer research 2007;6718:8772-8782